Many people with dry eye disease do not achieve sufficient relief with over-the-counter eye drops and lifestyle modifications.1
Ciclosporin has been endorsed by the global guidelines of the Tear Film and Ocular Surface Society Dry Eye Workshop (TFOS DEWS) II as a second-line treatment option for dry eye disease, when first-line interventions do not provide adequate relief.1
Cequa (ciclosporin 900 mcg/mL) is an aqueous, nanomicellar, ophthalmic, ciclosporin solution indicated to increase tear production in moderate to severe dry eye disease where prior use of artificial tears has not been sufficient.2 Available as a private prescription, Cequa is also available on the Pharmaceutical Benefits Scheme (PBS) for a subsection of patients living with chronic severe dry eye disease with keratitis.3
Contact: Sun Pharma (AUS) 1800 726 229 or email customerservice.aus@sunpharma.com
PBS Information: Authority Required. Refer to PBS schedule for full authority information. Please review product information before prescribing, available from ebs.tga.gov.au
References
- Jones L, et al. Ocular Surf. 2017. doi: 10.1016/j.jtos.2017.05.006.
- Cequa approved product information.
- Pharmaceutical Benefits Scheme (pbs.gov.au).
